Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2

Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2

Summary: Background: To address the emergence of SARS-CoV-2, multiple clinical trials in humans were rapidly started, including those involving an oral treatment by nitazoxanide, despite no or limited pre-clinical evidence of antiviral efficacy. Methods: In this work, we present a complete pre-clin...

Full description

Bibliographic Details
Main Authors:	Jean-Sélim Driouich, Maxime Cochin, Franck Touret, Paul-Rémi Petit, Magali Gilles, Grégory Moureau, Karine Barthélémy, Caroline Laprie, Thanaporn Wattanakul, Palang Chotsiri, Richard M. Hoglund, Joel Tarning, Laurent Fraisse, Peter Sjö, Charles E. Mowbray, Fanny Escudié, Ivan Scandale, Eric Chatelain, Xavier de Lamballerie, Caroline Solas, Antoine Nougairède
Format:	Article
Language:	English
Published:	Elsevier 2022-08-01
Series:	EBioMedicine
Subjects:	COVID-19 SARS-CoV-2 Antiviral therapy Pre-clinical research Nitazoxanide Animal model
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352396422003292

Similar Items

Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2
by: Driouich, J-S, et al.
Published: (2022)

Comparison Between Nitazoxanide and Metronidazole in the Treatment of Protozoal Diarrhea in Children
by: Asmaa A.E. Ali, et al.
Published: (2014-06-01)

Activity of Nitazoxanide Against Viral Gastroenteritis: A Systematic Review
by: Eugene Tan, et al.
Published: (2017-08-01)

Further preclinical characterization of molnupiravir against SARS-CoV-2: Antiviral activity determinants and viral genome alteration patterns
by: Paul-Rémi Petit, et al.
Published: (2024-05-01)

Pulmonary cryptosporidiosis in an immunocompetent host treated successfully with nitazoxanide
by: Harish Kumar, et al.
Published: (2016-01-01)

Plant-Waste-Derived Sorbents for Nitazoxanide Adsorption
by: Artur Sokołowski, et al.
Published: (2023-08-01)

Cryptosporidial diarrhea in an immunocompetent adult: role of nitazoxanide
by: Naba Raj Mainali, et al.
Published: (2013-12-01)

Efficacy of Nitazoxanide, Nitazoxanide-Garlic Combination and Tinidazole in Treatment of Giardia duodenalis and Blastocystis hominis: Coproscopic Assessment
by: Sarah Mohamed Abdo, et al.
Published: (2023-03-01)

Octaarginine Improves the Efficacy of Nitazoxanide against <i>Cryptosporidium parvum</i>
by: Tran Nguyen-Ho-Bao, et al.
Published: (2022-06-01)

In vitro anthelmintic activity of nitazoxanide in comparison to praziquantel against Eurytrema coelomaticum
by: Rafael Luiz Olivo, et al.
Published: (2022-10-01)

Combination therapy of nitazoxanide with oseltamivir compared with oseltamivir in hospitalized patients with seasonal influenza
by: Parvaiz A Koul, et al.
Published: (2024-01-01)

Antiviral activity of nitazoxanide against Morbillivirus infections
by: Debora Stelitano, et al.
Published: (2023-12-01)

Repurposing Nitazoxanide for Potential Treatment of Rare Disease Lymphangioleiomyomatosis
by: Stella Bähr, et al.
Published: (2024-09-01)

Rural treatment of COVID-19 patients with pirfenidone, nitazoxanide and colchicine. Case series
by: Brandon Iturbe Esquivel, et al.
Published: (2022-06-01)

In vivo evaluation the efficiency of nitazoxanide with cationic Gemini surfactant on Cryptosporidiosis
by: Zeinab Ahmed, et al.
Published: (2023-12-01)

Comparison of Therapeutic Effect of Anti-Cryptosporidium Nano-Nitazoxanide (NTZ) with Free form of this Drug in Neonatal Rat
by: F. Sedighi, et al.
Published: (2016-09-01)

Transcriptional Differential Analysis of Nitazoxanide-Mediated Anticanine Parvovirus Effect in F81 Cells
by: Xia Su, et al.
Published: (2024-02-01)

Nitazoxanide mitigates methotrexate hepatotoxicity in rats: role in inhibiting apoptosis and regulating endoplasmic reticulum stress
by: Nevertyty Mohamed Mahmoud, et al.
Published: (2024-12-01)

The clinical antiprotozoal drug nitazoxanide and its metabolite tizoxanide extend Caenorhabditis elegans lifespan and healthspan
by: Wenfeng Li, et al.
Published: (2024-07-01)

Nitazoxanide, an Antiprotozoal Drug, Reduces Bone Loss in Ovariectomized Mice by Inhibition of RANKL-Induced Osteoclastogenesis
by: Chang-hong Li, et al.
Published: (2021-12-01)

Repurposing Benztropine, Natamycin, and Nitazoxanide Using Drug Combination and Characterization of Gastric Cancer Cell Lines
by: Eduarda Ribeiro, et al.
Published: (2023-03-01)

Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19?
by: Dina B. Mahmoud, et al.
Published: (2020-07-01)

Effect of nitazoxanide and spiramycin metronidazole combination in acute experimental toxoplasmosis
by: Amal FarahatAllam, et al.
Published: (2020-04-01)

Nitazoxanide Exerts Immunomodulatory Effects on Peripheral Blood Mononuclear Cells from Type 2 Diabetes Patients
by: Mauricio Castillo-Salazar, et al.
Published: (2021-12-01)

Corrigendum: Nitazoxanide, an antiprotozoal drug, reduces bone loss in ovariectomized mice by inhibition of RANKL-induced osteoclastogenesis
by: Chang-hong Li, et al.
Published: (2023-07-01)

Investigations of nitazoxanide molecular targets and pathways for the treatment of hepatocellular carcinoma using network pharmacology and molecular docking
by: Shakeel Ahmad Khan, et al.
Published: (2022-07-01)

Nitazoxanide and quercetin co-loaded nanotransfersomal gel for topical treatment of cutaneous leishmaniasis with macrophage targeting and enhanced anti-leishmanial effect
by: Sidra Bashir, et al.
Published: (2023-11-01)

Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19
by: Frauke Assmus, et al.
Published: (2022-08-01)

Macrophage targeting of nitazoxanide-loaded transethosomal gel in cutaneous leishmaniasis
by: Husna Khalid, et al.
Published: (2022-10-01)

Nitazoxanide synergizes polymyxin B against Escherichia coli by depleting cellular energy
by: Xuejia Jiang, et al.
Published: (2024-08-01)

Two nitazoxanide-based quadruple regimens for eradication of Helicobacter pylori infection: a single-center randomized controlled trial
by: Amro M Hassan, et al.
Published: (2022-01-01)

EFFICACY OF NITAZOXANIDE AGAINST Toxocara canis: LARVAL RECOVERY AND HUMORAL IMMUNE RESPONSE IN EXPERIMENTALLY INFECTED MICE
by: Susana A. Zevallos LESCANO, et al.
Published: (2015-08-01)

Evaluation of β-Catenin Inhibition of Axitinib and Nitazoxanide in Human Monocyte-Derived Dendritic Cells
by: Waqas Azeem, et al.
Published: (2021-08-01)

Dissolution Advantage of Nitazoxanide Cocrystals in the Presence of Cellulosic Polymers
by: Reynaldo Salas-Zúñiga, et al.
Published: (2019-12-01)

Need for a standardized translational drug development platform: lessons learned from the repurposing of drugs for COVID-19
by: Assmus, F, et al.
Published: (2022)

Atazanavir/Ritonavir Increased Tizoxanide Exposure from Oral Nitazoxanide through Pharmacokinetic Interaction in Healthy Volunteers
by: Abdulafeez Akinloye, et al.
Published: (2024-02-01)

Eco-sustainable chromatographic method for the determination of favipiravir and nitazoxanide for COVID-19: application to human plasma
by: Amal B. Ahmed, et al.
Published: (2025-01-01)

Comparative efficacy and safety of anti-cryptosporidial agents: an in vitro study on nitazoxanide, halofuginone lactate, KDU731, and paromomycin against Cryptosporidium parvum
by: Saffron T. G. Whitta, et al.
Published: (2024-10-01)

Investigating the Biological Potency of Nitazoxanide-Based Cu(II), Ni(II) and Zn(II) Complexes Synthesis, Characterization and Anti-COVID-19, Antioxidant, Antibacterial and Anticancer Activities
by: Abeer A. Sharfalddin, et al.
Published: (2023-08-01)

Antiparasitic nitazoxanide potentiates colistin against colistin-resistant Acinetobacter baumannii and Escherichia coli in vitro and in vivo
by: Mengxin Xu, et al.
Published: (2024-01-01)